Beacon Biosignals closed an $86 million financing to scale a longitudinal brain‑wave dataset intended to accelerate drug development and diagnostics for neurological diseases. The company will expand data collection infrastructure, recruit more clinical sites, and invest in analytics to link electrophysiological signatures with clinical outcomes. Investors framed the round as a bet on data‑driven neurology tools that can de‑risk trials and enable objective endpoints. Clarification: the company aims to monetize de‑identified EEG datasets and derived biomarkers for sponsor studies and regulatory submissions.